An interventional study of CamAPS HX and Standard insulin therapy in Perioperative Hyperglycaemia, Insulin Therapy and Elective Surgery, sponsored by Lia Bally. Completed at 2 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-17.
Sponsored by Lia Bally · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Liver Diseases with a site in Switzerland — 5 open to participants now, 6 under way, 2 of them phase 3. Liver Diseases · Switzerland.
Among the 20 studies in Liver Diseases with a site in Switzerland, this one is the 10th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2022, is one of 4 with no phase, and was the 18th registered.
825 studies on the registry are indexed under Liver Diseases; 153 are open to participants now.
Browse Liver Diseases studies →5 of the 20 studies in Liver Diseases with a site in Switzerland are open now. Recruiting first, the newest first:
Thomas Jefferson University · Sites in Switzerland, United States
Ages 18+
University Hospital, Basel, Switzerland · Sites in Switzerland
Ages 18+ · Healthy volunteers
European Foundation for Study of Chronic Liver Failure · Sites in Switzerland, United States, Argentina and 24 more countries
Ages 18–80
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18+
University Hospital, Geneva · Sites in Switzerland
Ages up to 18
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 105 Liver Diseases studies recruiting now, 52 (50%) set no upper age limit and 30 (29%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 6 · Phase 3 2
First in 2006; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 38 is below the median of 52 across 522 interventional studies indexed under Liver Diseases.
Median enrollment 80 across the 15 interventional studies, 277 across the 5 observational. Of the 10 that completed or were terminated, 2 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 20 have an industry lead sponsor. The 10 most frequent:
Lia Bally is the lead sponsor of 15 studies on the registry; none are open to participants now.
Lia Bally has 1 study filed under Liver Diseases — fewer than ten, so there is no comparison to draw.
4 of the studies in Liver Diseases with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04874428Insel Gruppe AG, University Hospital BernDirect Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis | 2026-12 |
| NCT04613921European Foundation for Study of Chronic Liver FailureLiver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs | 2026-12-31 |
| NCT05385237University Hospital, Basel, SwitzerlandIdentification of Hepatic Fibrosis Using 4D-MRI | 2026-12-31 |
| NCT05063565Boston Scientific CorporationTheraSphere With Durvalumab and Tremelimumab for HCC | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 20 studies in Liver Diseases with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to assess the efficacy, safety and usability of perioperative fully-automated closed-loop insulin delivery versus standard insulin therapy in patients with diabetes other than type 1 diabetes undergoing elective major abdominal surgery.
The prevalence of diabetes and hyperglycaemia in surgical patients is rising and associated not only with greater complication rates, length of stay, morbidity and mortality rates, but also increased hospital costs and readmission rates. Due to the complex interaction of organs involved in glucose homeostasis (e.g. liver, pancreas) and the frequent need for nutrition support, patients undergoing major abdominal surgery are particularly prone to develop dysglycaemia. While there are guidelines for perioperative glucose management, implementation is challenging and inconsistent. Main reasons are lack of resources, clinical inertia based on fear of hypoglycaemia and multiple handovers between teams.
Closed-loop glucose control represents an emerging diabetes treatment modality that autonomously adjusts insulin delivery according to continuously measured glucose levels. The use of fully automated closed-loop insulin delivery may represent an easy-to-adopt approach for safe and effective perioperative diabetes management. In previous work, the investigators demonstrated that fully closed-loop insulin delivery in adults with type 2 diabetes undergoing various elective surgeries (abdominal, vascular, neurologic, orthopaedic, thoracic) improved glycaemic control by increasing time spent in the glycaemic target range, lowering mean sensor glucose and glycaemic variability without increasing the risk of hypoglycaemia.
In this follow-up trial the investigators will focus on patients undergoing major elective abdominal surgery to further explore the potential of the fully automated closed-loop approach to accommodate the complex needs of this population. Involvement of a second study centre and hospital staff for device management will further allow to assess the usability of the fully closed-loop system for larger multi-centre clinical trials as well as readiness to use the approach in usual clinical care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intervention: Use of a fully-automated closed-loop insulin delivery system from day of admission until hospital discharge (or maximum 20 days).
Device: CamAPS HX
The control group will receive insulin therapy in accordance with local practice. The insulin regimen during the study period may involve subcutaneous and/or insulin intravenous insulin administration. The modality of insulin treatment, dose adjustment and frequency of glucose monitoring will be at the discretion of the clinical team. No active treatment optimisation will be undertaken by the study team. Participants in the control group will be fitted with the identical study CGM system. The CGM system will be blinded upon hospital admission.
Drug: Standard insulin therapy
Fully automated closed-loop subcutaneous insulin delivery system. A model predictive controller modulates insulin delivery every 10-12 minutes based on interstitial glucose measurements.
Standard insulin therapy according to local clinical practice.
The proportion of time spent in the target glucose range from 5.6 to 10.0 mmol/L
The outcome is based on sensor glucose levels
Time frame: Assessed from hospital admission until a maximum of 20 days following surgery
Proportion of time spent with sensor glucose values above target (> 10.0 mmol/L)
The outcome is based on sensor glucose levels
Time frame: Assessed from hospital admission until a maximum of 20 days following surgery
Proportion of time spent with sensor glucose <3.0 mmol/L
The outcome is based on sensor glucose levels
Time frame: Assessed from hospital admission until a maximum of 20 days following surgery
Proportion of time spent with sensor glucose < 3.9 mmol/L
The outcome is based on sensor glucose levels
Time frame: Assessed from hospital admission until a maximum of 20 days following surgery
Average of sensor glucose level
The outcome is based on sensor glucose levels
Time frame: Assessed from hospital admission or until a maximum of 20 days following surgery
Proportion of time spent with sensor glucose below target (< 5.6 mmol/L)
The outcome is based on sensor glucose levels
Time frame: Assessed from hospital admission until a maximum of 20 days following surgery
Standard deviation of sensor glucose levels
The outcome is based on sensor glucose levels
Time frame: Assessed from hospital admission or until a maximum of 20 days following surgery
Coefficient of variation of sensor glucose levels
The outcome is based on sensor glucose levels
Time frame: Assessed from hospital admission until a maximum of 20 days following surgery
Total daily insulin dose
Insulin dose received by the patients in units/24h
Time frame: Assessed from hospital admission until a maximum of 20 days following surgery
Post-surgery comorbidity
Assessed using the Comprehensive Complication Index (CCI)
Time frame: Assessed at 30 days following surgery
Length of hospital stay
Assessed based on the information in electronic health records
Time frame: Up to 20 days
Peri- and postoperative costs (perspectives: hospital, statutory health insurance system)
Assessed based on the information from device manufacturers, hospital administration system and standard external sources for healthcare utilisation unit costs.
Time frame: Assessed from hospital admission until a maximum of 30 days following surgery
Number of severe hypoglycaemia (< 2.2 mmol/L)
Based on point-of-care capillary measurements. This is a safety outcome.
Time frame: Assessed from hospital admission until a maximum of 20 days following surgery
Number of clinically significant hyperglycaemic events (>20.0 mmol/L) with ketonaemia (beta-hydroxybutyrate >1.0 mmol/L)
Based on point-of-care capillary measurements. This is a safety outcome
Time frame: Assessed from hospital admission until a maximum of 20 days following surgery
Ran from Aug 2022 to primary completion in Oct 2023, 14 months.
Of 122 non-industry interventional studies with no phase under Liver Diseases, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 50. This study's 14 months is below that.
Counting every sponsor, half of 135 studies reached it within 24 months; a quarter within 12 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lia Bally